We’re at a pivotal moment with the current breakthroughs in Alzheimer’s drug development, but there is still work to do. Mark Roithmayr spoke with the PharmaBoardroom about the latest advancements in the field that are bringing us closer to conquering Alzheimer’s disease and the path forward that requires bold investments in early-stage research, increased collaboration, and a commitment to funding innovative science. By investing in a diverse pipeline of potential therapies and moving capital toward these pivotal ideas we can take significant step in addressing #Alzheimer’s.
Alzheimer's Drug Discovery Foundation
研究服务
New York，NY 14,941 位关注者
Alzheimer's Drug Discovery Foundation (ADDF) is the only charity solely focused on finding drugs for Alzheimer's
关于我们
Conquering Alzheimer’s Through Drug Discovery. Founded in 1998 by Leonard A. Lauder and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation (ADDF) was one of the first charities to adopt the venture philanthropy model. Our mission is to rapidly accelerate the discovery of drugs to prevent and treat Alzheimer’s disease and related dementias. We are the only charity focused solely on supporting new drugs for Alzheimer’s. The ADDF’s in-house team of six expert neuroscientists identifies and funds the most promising research initiatives around the world. They work to ensure that every viable option to prevent or treat Alzheimer’s is explored, and that the pipeline of drugs in development for Alzheimer’s is both diverse and robust. Since 1998, we have awarded over $100 million to fund more than 550 Alzheimer’s drug discovery programs and clinical trials in 18 countries. Today, 20% of all treatments for Alzheimer’s in clinical trials have received support from the ADDF.
- 网站
-
https://www.alzdiscovery.org
Alzheimer's Drug Discovery Foundation的外部链接
- 所属行业
- 研究服务
- 规模
- 11-50 人
- 总部
- New York，NY
- 类型
- 非营利机构
- 创立
- 1998
- 领域
- Neuroscience、Drug Discovery、Biomarker Development和Cognitive Aging
地点
-
主要
获取路线
57 West 57th Street
Suite 904
US，NY，New York，10019
Alzheimer's Drug Discovery Foundation员工
动态
-
Alzheimer's Drug Discovery Foundation转发了
The Alzheimer's Drug Discovery Foundation team is ready to welcome guests for the 8th Annual #MemoriesMatter Gala! It’s going to be a great night! Thanks to all who put in the effort to make it so very special! #ADDF #NYC American Museum of Natural History
-
-
Globally, two-thirds of people with Alzheimer’s disease are female. A recent article in Nature Medicine sheds light on the biological changes in the female brain that may contribute to women developing Alzheimer’s disease. Leading researchers including ADDF Goodes Prize winner Roberta Diaz Brinton along with Lisa Mosconi, Michelle Mielke, and Justina Avila-Rieger explore how hormonal shifts and metabolic differences could increase women’s vulnerability to Alzheimer’s. Understanding these sex-specific risk factors is critical to advancing prevention and treatments. This research marks a major step forward in addressing these gaps.?
-
In a recent Fox News Media interview, Howard Fillit, MD, discusses the new findings from Washington University in St. Louis on the experimental anti-amyloid drugs that?have shown promise in preventing Alzheimer’s for people at higher risk of developing the disease. "One day soon, we may be delaying the onset of Alzheimer’s disease for millions,” said Dr. Fillit, co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundation, noting that the study shows for the first time that early treatment to clear the plaques before symptoms arise can delay the onset of Alzheimer’s — "similar to how we treat and prevent other chronic diseases." https://fxn.ws/4ckMZLr
-
Alzheimer's Drug Discovery Foundation转发了
We are honored to partner with the Alzheimer's Drug Discovery Foundation (ADDF) for the Eighth Annual Memories Matter event on Wednesday, March 26, 2025, at the American Museum of Natural History in New York City. This special evening is dedicated to advancing groundbreaking research in Alzheimer’s disease, with 100% of funds raised going directly toward cutting-edge science. The ADDF’s work is driving real progress toward developing the next generation of treatments, and we are proud to stand alongside them in this mission. Join us in supporting this critical cause. Donate today to help fund life-changing research: https://lnkd.in/e4WAARJe
-
-
Exciting news in Alzheimer’s research from our funded investigators Modulo Bio announcing our strategic investment to advance the development of its innovative CSF1R inhibitor for the treatment of Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). This novel research combats neuroinflammation in degenerative brain disorders.
I'm thrilled to announce that Modulo Bio has secured a $4.8M strategic investment from the Alzheimer's Drug Discovery Foundation (ADDF)! This funding will accelerate the development of our novel CSF1R inhibitor targeting Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). This investment is a powerful validation of our mission to reprogram the brain's immune system to combat neurodegenerative diseases. Our approach focuses on modulating microglial cells, the brain's primary immune cells, which play a crucial role in neuroinflammation and disease progression. This funding will support IND-enabling studies and bring our CSF1R inhibitor closer to clinical trials. I'm incredibly proud of our team's work and grateful for ADDF's belief in our vision to deliver new hope to patients with devastating neurodegenerative conditions.
-
We are thrilled to present a special look back at our Inaugural ADDF Scientific Summit held earlier this month. The evening commenced with insightful remarks from Mark Roithmayr, highlighting ADDF’s groundbreaking contributions to #Alzheimer’s research. Daniel Skovronsky, Chief Scientific Officer of Eli Lilly and Company, received our prestigious 11th annual Melvin R. Goodes Prize, known as the Nobel Prize of Alzheimer’s research, in recognition of his outstanding work in drug development. The event was hosted by Howard Fillit, MD which brought together eight of the ten prior recipients of the esteemed Goodes Prize for a symposium led by Niranjan Bose, featuring a special address from Dr. Sanjay Gupta. Thanks to the support of the top leaders and innovators in the industry, we continue to be committed to advancing innovation in our fight against Alzheimer’s.
-
Promising new research from Washington University School of Medicine in St. Louis shows that early intervention with anti-amyloid drugs may reduce the risk of Alzheimer’s in people destined to develop Alzheimer’s disease in their 30s, 40s and 50s. Published in?The Lancet Neurology?on March 19, the international study involved 73 individuals carrying a rare genetic mutation that typically leads to early-onset Alzheimer’s. We’ve entered into a new era of Alzheimer’s research where we can not only modify the course of the disease, but where prevention is possible with therapeutic intervention. https://bit.ly/4hsnx7A
-
-
Congratulations to our friends and partners ALZpath Inc., one of the Diagnostics Accelerator portfolio companies for being recognized as one of Fast Company's Most Innovative Biotech Companies of 2025! Their work in advancing a simple blood test to diagnose Alzheimer’s at an early stage is revolutionizing clinical care and research.?
ALZpath Inc. Named to Fast Company's Most Innovative Companies of 2025! We’re honored to be recognized by FastCompany as one of the World’s Most Innovative Companies of 2025, joining the ranks of NVIDIA, YouTube, and other top innovators shaping the future.? ALZpath’s proprietary pTau217 antibody, already integral to many of the most advanced and widely available blood tests, is transforming early Alzheimer’s disease diagnosis by enabling highly sensitive and accurate detection of a key Alzheimer’s disease biomarker—well before symptoms appear.? With Alzheimer’s disease expected to impact 153 million people globally by 2050, the urgency for accessible, scalable, and non-invasive diagnostics has never been greater. Through partnerships with Roche Diagnostics USA, Beckman Coulter Diagnostics, Bio-Techne, Alamar Biosciences, Inc., and Quanterix, ALZpath is bringing cutting-edge blood-based diagnostics to researchers, clinicians, and patients worldwide.? "Many patients with Alzheimer's today don’t have a clear diagnosis, in part because the most reliable current diagnostic methods are costly, invasive, and can only be administered at specialized facilities," said Mike Banville, CEO & President of ALZpath. "In partnership with leading diagnostic companies, ALZpath is making our best-in-class antibody for detecting Alzheimer’s disease widely available in easy-to-administer, affordable blood tests, which we believe will vastly improve care and outcomes for millions of families facing Alzheimer’s disease.”? "Through our licensing agreements we are empowering researchers, clinicians, and industry partners to accelerate the discovery of new treatments," said?Jacob Hunter, Chief Business Officer of ALZpath. "Critically, this increased access supports the growing urgency to expand blood-based testing in research and clinical settings—enabling early identification of patients for novel treatments that have recently entered the clinical sphere, monitoring treatment response, and building robust evidence for the efficacy of novel therapies. Additionally, these efforts advance our understanding of Alzheimer's disease and validate new targeted approaches to treat and potentially prevent the disease." Being named to Fast Company’s Most Innovative Companies list reinforces our mission to expand access to early, accurate Alzheimer’s disease diagnosis—making detection, treatment, and monitoring more widely available than ever before.? ?? Read the full press release here: https://lnkd.in/gVCcSpic? ?? View the full list from Fast Company here: https://lnkd.in/gatBDGKy #FastCompany #FCMostInnovative #AlzheimersResearch #Innovation #Healthcare #Diagnostics #pTau217
-
-
Menopausal hormone therapy has been long debated for its effect on brain health, new research from the Kronos Early Estrogen Prevention Study (KEEPS) Continuation Study shows no long-term cognitive effects of hormone therapy when started in early menopause. The latest Cognitive Vitality blog from the ADDF’s Aging and Prevention team breaks down the science behind hormone therapy, its potential benefits, and what women should consider when weighing their options. https://bit.ly/3FwGqcj